ImmunityBio just hit a huge milestone – they can now mass-produce and freeze powerful NK cells from healthy and cancer donors. One simple blood draw gives 8–10 ready-to-use doses.
ImmunityBio’s ANKTIVA + BCG just received European Commission approval – the first new immunotherapy in Europe for hard-to-treat bladder cancer. Now available in 33 countries, offering hope without surgery.
ImmunityBio advances FDA talks for ANKTIVA in papillary bladder cancer. Treatment shows 96% survival & 80% avoid bladder removal at 3 years, offering hope vs. current option: invasive surgery.
ImmunityBio shares surge with 10-day winning streak as ANKTIVA cancer drug revenue jumps 700% to $113M. Saudi approval and analyst targets signal more upside ahead.
ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.
ImmunityBio stock climbed 8.5% after European regulators recommended approval for Anktiva, a bladder cancer treatment that helped over 70% of patients in clinical trials.
